Overview
Location
France, Ile-de-France, Paris
Employees
1001-5000
Phone
+33 1 56 24 55 00
Founded date
1909
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 29, 2025 | Primaa raises €7M to accelerate product growth and international expansion | Paris-based Primaa, a developer of AI software for automated, accurate histological and cancer diagnostics, has extended its financing round to €7 million. The round is backed by the partnership fund between MH Innov’ and Elaia, and SWEN Ca... |
| Jul 17, 2025 | One Biosciences Raises €15M in Series A Funding | One Biosciences, a Paris, France-based precision oncology techbio company, raised €15M in Series A funding. The round was led by Redmile Group and Blast, with participation from Galion.exe, Invus, Adamed Technology, Sofinnova Partners, Poly... |
| Jul 17, 2025 | One Biosciences raises €15M Series A to advance precision oncology platform | One Biosciences, a precision oncology biotech company pioneering clinical grade single-cell tumour profiling, today announced €15 million Series A financing, bringing the company’s funding to €20 million. One Biosciences aims to help clinic... |
| Apr 25, 2024 | PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers | Press release PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers Paris (France), April 25, 2024 – PEP-Therapy, a clinical-stage biotechnology company ... |
| Apr 25, 2024 | PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas | Communiqué de presse PEP-Therapy et l’Institut Curie annoncent le traitement des premiers patients dans la phase Ib de l’essai clinique évaluant PEP-010 dans les cancers de l’ovaire et du pancréas Paris (France), le 25 avril 2024 – PEP-Ther... |
| Oct 22, 2021 | Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers About Egle Therapeutics About LSP About Bpifrance – InnoBio 2 About Takeda Ventures Inc. About Fund+ About Bioqube Ventures About Institut Curie | Egle Therapeutics SAS (Egle), an emerging biotechnology company focused on developing First-In- Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, today announces that it has c... |
| May 19, 2021 | Prestigious French cancer center Institut Curie digitizes pathology with solution from Sectra | Prestigious French cancer center Institut Curie digitizes pathology with solution from Sectra Wed, May 19, 2021 08:35 CET Linköping, Sweden – May 19, 2021 – International medical imaging IT and cybersecurity company Sectra (STO: SECT B) wil... |
| Dec 17, 2013 | Curie-Cancer and Strand Launch Curie Image Database | PARIS and SAN FRANCISCO, December 17, 2013 /PRNewswire/ -- |
| Egle Therapeutics raises 40 million € Series A to develop First-In-Class T-regulatory cells therapies based on Treg-starvers | LSP and Bpifrance, through its InnoBio 2 Fund, co-led international investor syndicate |
Reviews 0
FAQ about Institut Curie
When was Institut Curie founded?
Institut Curie was founded in 1909.
What has the press written about Institut Curie?
Parsers VC has collected 10 articles mentioning Institut Curie, among them “Primaa raises €7M to accelerate product growth and international expansion” (Oct 29, 2025) and “One Biosciences Raises €15M in Series A Funding” (Jul 17, 2025).
Is Institut Curie still active?
Yes, Institut Curie is active; its latest activity on Parsers VC dates from May 26, 2026.